Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
MNPR 
Monopar Therapeutics Inc (MNPR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/02/2026: MNPR (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $111.77
1 Year Target Price $111.77
| 2 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 544.46% | Avg. Invested days 55 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 01/02/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 441.12M USD | Price to earnings Ratio - | 1Y Target Price 111.77 |
Price to earnings Ratio - | 1Y Target Price 111.77 | ||
Volume (30-day avg) 5 | Beta 1.47 | 52 Weeks Range 22.50 - 105.00 | Updated Date 01/4/2026 |
52 Weeks Range 22.50 - 105.00 | Updated Date 01/4/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.96 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -17.99% | Return on Equity (TTM) -26.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 297512463 | Price to Sales(TTM) - |
Enterprise Value 297512463 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.42 | Shares Outstanding 6682584 | Shares Floating 4228004 |
Shares Outstanding 6682584 | Shares Floating 4228004 | ||
Percent Insiders 23.82 | Percent Institutions 65.08 |
About Monopar Therapeutics Inc
Exchange NASDAQ | Headquaters Wilmette, IL, United States | ||
IPO Launch date 2019-12-19 | Co-Founder, CEO, President & Director Dr. Chandler D. Robinson M.B.A., M.D., M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.monopartx.com |
Full time employees 14 | Website https://www.monopartx.com | ||
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.